Posted by Michael Wonder on 13 Dec 2023
Pembrolizumab and chemotherapy with or without bevacizumab for patients with persistent, recurrent or metastatic cervical cancer
13 December 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) and chemotherapy with or without bevacizumab for the treatment of adults with persistent, recurrent or metastatic cervical cancer.
Pembrolizumab and chemotherapy with or without bevacizumab is recommended as an option for the treatment of adults with persistent, recurrent or metastatic cervical cancer whose tumours express PD‑L1 with a combined positive score of at least 1.
It is recommended only if: pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and the Merck/MSD provides it according to the commercial arrangements.
